

# Ensuring Safe Medicines for a Healthy Life: The Importance of ADR Monitoring

Prof.(Dr.) Mohd. Wasiullah<sup>1</sup>, Prof. (Dr.) Piyush Yadav<sup>2\*</sup>, Mohit Vishwakarma<sup>3</sup>, Mukul Yadav<sup>4</sup>

Date of Submission: 25-04-2025

Date of Acceptance: 05-05-2025

## ABSTRACT

Adverse Drug Reactions (ADRs) are unintended and harmful effects of medications that threaten patient safety and burden healthcare systems. ADR monitoring, also known as pharmacovigilance, is essential for detecting, assessing, and preventing these reactions throughout a drug's lifecycle. While it improves treatment outcomes and supports regulatory decisions, challenges such as underreporting, limited awareness, and resource constraints persist. Strategies including electronic health record integration, artificial intelligence, patient involvement, and international collaboration can enhance monitoring efforts. Strengthening pharmacovigilance is crucial for ensuring medication safety, reducing healthcare costs, and maintaining public trust.

**KEYWORDS:** Pharmacovigilance, Adverse Drug Reactions (ADRs), Drug Safety, Underreporting, Healthcare Systems.

## I. INTRODUCTION

Adverse drug reactions (ADRs) are unintended and harmful effects of medications, ranging from mild side effects to severe complications. Ensuring the safety of medicines is crucial in healthcare, requiring continuous vigilance and monitoring. ADR monitoring, also known as pharmacovigilance, is a systematic process aimed at detecting, assessing, understanding, and preventing adverse effects associated with medications. It helps healthcare professionals, regulatory authorities, and pharmaceutical companies identify potential risks early and take corrective measures. Without proper ADR monitoring, harmful drugs may remain on the market for extended periods, leading to widespread health issues and even fatalities. ADR monitoring also contributes to the refinement of drug formulations, improvement of treatment guidelines, and strengthening regulatory policies. By identifying trends in drug reactions, researchers can modify existing medicines or develop safer alternatives. It also promotes public confidence in

healthcare systems by ensuring transparency and accountability in drug safety assessments. [1]

### 1.1 Definition of Adverse Drug Reactions (ADRs)

Adverse Drug Reactions (ADRs) are unintended and harmful effects of drugs administered at normal therapeutic doses for disease prevention, diagnosis, treatment, or physiological function modification. They can lead to increased hospitalization, prolonged treatment, additional costs, and fatal outcomes, making ADR monitoring crucial for drug safety and patient care. Unlike medication errors or overdoses, ADRs occur even when used correctly. [2]

### 1.2 Scope of ADRs

ADRs are a significant cause of hospital admissions and medical complications, accounting for 5-10% of hospitalizations worldwide. The World Health Organization reports that ADRs are one of the top 10 leading causes of mortality in some countries. They affect all drug classes and patient populations, with certain populations, such as the elderly, children, and those with chronic illnesses, being more susceptible. Polypharmacy increases the risk of drug-drug interactions, leading to ADRs. ADRs occur in hospitals, causing extended stays and increased treatment costs, and in outpatient clinics, requiring close monitoring by healthcare providers. [3]

### 1.3 Impact of ADRs

ADRs can significantly impact patient health, leading to increased morbidity and mortality, reduced quality of life, and non-adherence to medication. They also increase hospital admissions, length of stays, and medical interventions, costing billions of dollars globally. Preventable ADRs could save significant healthcare resources if properly monitored and managed. Post-marketing ADRs can lead to drug recalls, warnings, or restricted use, requiring

stricter safety evaluations by regulatory agencies like the FDA, EMA, and WHO. The pharmaceutical industry invests heavily in risk management programs to monitor ADRs. Legal and ethical considerations include potential lawsuits against pharmaceutical companies and healthcare providers, emphasizing the need for transparency in reporting ADRs to protect patients.[4]

#### 1.4 Importance of ADR Monitoring

Adverse Drug Reaction (ADR) monitoring is crucial for patient safety, drug efficacy, and healthcare systems. ADRs can lead to severe health complications, prolonged hospital stays, and even fatalities, making it essential to minimize risks and ensure safe medication use. Continuous monitoring helps in early detection of adverse effects, allowing healthcare professionals to take necessary precautions, adjust dosages, or required certain drugs which discontinued ADR monitoring also impacts drug regulation and policy-making, as regulatory agencies like the World Health Organization, the U.S. Food and Drug Administration, and the European Medicines Agency rely on ADR data to assess the safety of medications. ADR monitoring contributes to the economic sustainability of healthcare systems, as the treatment of ADR-related complications significantly increases healthcare costs. By actively monitoring ADRs, healthcare providers can identify high-risk medications early, reduce unnecessary hospital admissions, and lower the financial burden on patients and healthcare institutions. Pharmacovigilance, which includes ADR monitoring, plays a key role in drug development and post-marketing surveillance. Continuous monitoring after a drug is marketed ensures the identification and study of rare or long-term ADRs, providing valuable data for future drug formulation and treatment guidelines. {5}

ADR monitoring is essential in fostering public trust in the healthcare system, as patients and healthcare professionals are more likely to adhere to prescribed treatments and report any adverse effects, leading to better medication management and improved treatment outcomes.

## II. BENEFITS AND STRATEGIES OF ADR MONITORING

### 2.1 Benefits of ADR Monitoring

Adverse Drug Reaction (ADR) monitoring is a vital aspect of pharmacovigilance that enhances medication safety, improves patient outcomes, and

strengthens healthcare systems. It detects and prevents harmful drug reactions, enabling healthcare professionals to adjust or discontinue medications before they cause severe complications, reducing hospitalizations and improving treatment outcomes. Post-marketing ADR monitoring provides real-world data that refines drug safety profiles, leading to better risk-benefit assessments and improved prescribing guidelines. ADR monitoring also reduces healthcare costs by preventing medication-related complications that require additional treatments, prolonged hospital stays, Regulatory agencies like the FDA, EMA, and WHO use ADR data to update drug labels, issue safety warnings, and withdraw harmful medications when necessary. This proactive approach maintains the integrity of the pharmaceutical industry and ensures only safe and effective drugs remain available. ADR monitoring also promotes patient confidence and adherence to treatment, as patients are more likely to trust their prescribed treatments and report any adverse effects.[5]

### 2.2 Strategies for Effective ADR Monitoring

Healthcare systems must implement robust strategies to maximize the benefits of adverse drug reactions (ADR) monitoring. Spontaneous reporting systems (SRS) are essential for voluntarily reporting suspected ADRs to regulatory authorities, such as the WHO's VigiBase, FDA's MedWatch, and EMA's EudraVigilance. Active surveillance through pharmacovigilance programs enhances the detection of ADRs that might otherwise go unreported due to underreporting in voluntary system. [6]

The integration of artificial intelligence (AI) and big data analytics is transforming ADR monitoring. Machine learning algorithms can analyze large datasets from patient records, social media, and clinical trials more efficiently than traditional methods, predicting potential ADRs before they become widespread. Training and awareness programs for healthcare professionals and patients are essential for increasing ADR reporting rates.

Collaborative international efforts, such as the WHO and the International Council for Harmonisation (ICH), work to standardize reporting procedures and share ADR data across borders, ensuring a coordinated response to emerging drug safety issues. Overall, these

strategies aim to improve the detection, reporting, and prevention of ADRs in healthcare systems. [7]

### 2.3 Improved Patient Safety Through ADR Monitoring

Adverse Drug Reaction (ADR) monitoring is a critical aspect of healthcare systems, ensuring patient safety by detecting, preventing, and managing these reactions. ADRs, which occur when a patient experiences unintended and harmful effects from a medication, can lead to severe health complications, prolonged hospital stays, and even mortality. Effective ADR monitoring helps detect, prevent, and manage these reactions, significantly enhancing overall patient safety.

Early detection is key to ADR monitoring, as many ADRs develop over time and may not be immediately noticeable, especially in chronic medication use. By tracking and reporting adverse effects, healthcare professionals can identify potential risks before they escalate into severe complications. This allows for timely interventions, such as adjusting dosages, switching medications, or providing supportive treatments to counteract harmful reactions.

Unmonitored ADRs are a leading cause of hospital admissions worldwide, with 5-10% of these cases due to ADR-related complications. Proper pharmacovigilance can help prevent these cases and minimize hospital visits. Severe ADRs, such as anaphylactic reactions to antibiotics, liver toxicity from acetaminophen, or cardiac arrhythmias caused by certain medications, require immediate attention. Effective ADR monitoring ensures that these life-threatening reactions are reported and managed efficiently, ultimately lowering mortality rates associated with medication use. [8]

### 2.4 Enhancing Drug Safety and Regulatory Compliance

Pharmacovigilance systems, including Adverse Drug Reaction (ADR) monitoring, play a crucial role in the continuous assessment of drug safety. [9] Regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) rely on ADR reports to update drug safety guidelines, issue warnings, and, in some cases, withdraw unsafe medications from the market. [10]

Personalized medicine and safer prescribing practices are another benefit of ADR monitoring. Healthcare providers can tailor

treatments to individual patients by identifying which drugs are more likely to cause adverse reactions in specific populations. For example, patients with genetic variations in the CYP2C19 enzyme metabolize certain drugs differently, such as clopidogrel (Plavix), an antiplatelet medication. Pharmacogenetic studies based on ADR monitoring have led to personalized prescribing recommendations, improving drug effectiveness while reducing the risk of side effects. [11]

ADR monitoring aids in developing clinical decision support systems (CDSS) that provide healthcare professionals with real-time alerts on potential drug interactions, allergies, or contraindications. [12] This technology-based approach enhances patient safety by minimizing medication errors and ensuring appropriate prescriptions. Patient safety is also improved when individuals are actively involved in their treatment process. [13] Many healthcare systems have introduced patient-reported ADR monitoring systems, allowing individuals to report adverse effects directly. This approach increases awareness, encourages patient-provider communication, and leads to a more patient-centered approach to medication safety. [14]

### 2.5 strategies for effective ADR monitoring

Effective ADR monitoring is crucial for patient safety and improving pharmacovigilance systems. Key strategies include strengthening reporting systems, conducting regular training programs, integrating ADR reporting systems into electronic health records (EHR), educating patients on recognizing and reporting ADRs, using statistical tools for data analysis and signal detection, strengthening regulatory framework.

- a. Implement user-friendly ADR reporting platforms, encouraging voluntary and mandatory reporting from healthcare professionals and patients. [16]
- b. Conduct regular training programs on ADR recognition and reporting, including pharmacovigilance in medical and pharmacy education. [17]
- c. Integrate ADR reporting systems into EHRs, using AI and big data analytics for early detection. [18]
- d. Involve patients in recognizing and reporting ADRs, establishing patient-friendly reporting channels, and conducting surveys and feedback sessions. [19]

e. Strengthen regulatory frameworks by developing and enforcing ADR reporting policies and aligning with international guidelines.[20]

f. Encourage collaboration with pharmaceutical companies for post-marketing surveillance and global data sharing to improve drug safety. [21]

### III. CHALLENGES AND LIMITATIONS OF ADR MONITORING

Adverse Drug Reaction (ADR) monitoring is crucial for drug safety and patient well-being, but it faces several challenges and limitations. Underreporting of ADRs is a major issue, with only 5-10% of cases actually reported, leading to gaps in pharmacovigilance data. Factors contributing to underreporting include lack of awareness, time constraints, and the perception that reporting will not lead to meaningful action. [22]

The quality and completeness of ADR reports are also significant, as many lack critical details, reducing the reliability of ADR databases and hindering effective decision-making by regulatory authorities. [23] A lack of awareness and training among healthcare professionals further weakens ADR monitoring systems.

Patient involvement in ADR reporting is another challenge, as many patients do not recognize adverse reactions or are unaware of how to report them. Cultural and language barriers may further restrict patient participation, particularly in regions with low healthcare literacy.

Variability in ADR reporting systems across different countries and organizations adds complexity to the process. Global data sharing and comparison become challenging due to differing pharmacovigilance regulations. Technological limitations hinder the efficiency of ADR monitoring, as many healthcare systems still rely on manual reporting processes rather than leveraging AI and big data analytics. [24]

Resource and funding constraints also pose significant challenges, especially in developing countries where pharmacovigilance programs are often underfunded. Without adequate funding, even well-intended ADR monitoring initiatives may fail to achieve their objectives.

#### 3.1 Underreporting and Reporting Bias

Underreporting and reporting biases are significant challenges in monitoring adverse drug reactions (ADRs) among healthcare professionals. Key challenges include lack of awareness and knowledge, attitudes such as complacency, diffidence, and indifference, time constraints and

workload, and ignorance of the requirements and procedures for reporting ADRs.

Complacency is a common factor among HCPs, as they believe only safe drugs are marketed and ADRs are already well-documented. This complacency undermines the detection of rare or unexpected ADRs. Diffidence is another factor, as fear of appearing ridiculous or the belief that only certain ADRs are worth reporting can prevent HCPs from submitting reports.

Lethargy is another challenge, as procrastination, lack of time, and the perception that reporting is burdensome contribute to lethargy. [25] This results in delayed or omitted ADR reports. Indifference is another factor, as some HCPs may feel that a single report is inconsequential to medical knowledge, leading to indifference toward reporting ADRs.

To address these challenges, targeted educational initiatives, streamlined reporting processes, and fostering a culture that values and encourages ADR reporting among healthcare professionals are necessary. By addressing these challenges, healthcare professionals can work towards improving patient safety and the effective use of medications.

#### 3.2 Data Quality and Standardization

Data quality in ADR monitoring is crucial for ensuring the accuracy, completeness, reliability, and consistency of ADR reports. Poor data quality can lead to misinterpretation of safety signals and limit the effectiveness of regulatory actions. Incomplete or inaccurate data, such as patient demographics, drug dosage, or clinical outcomes, can result in difficulties in identifying causality between drugs and adverse reactions. [26]

Variability in data sources, including healthcare professionals, patients, pharmaceutical companies, and electronic health records (EHRs), also contributes to inconsistencies in data formats and terminology. Electronic health records may not capture all relevant ADR information due to differences in software systems used across healthcare institutions.

Causality assessment challenges are another issue in ADR monitoring. Determining whether an ADR is directly caused by a drug or due to other factors is complex, leading to many ADRs going unreported or misclassified. The WHO-Uppsala Monitoring Centre (WHO-UMC) causality assessment criteria exist, but subjective interpretation still plays a role.

Standardization challenges in ADR monitoring include the lack of a universal ADR reporting system, differences in terminologies and coding systems, and differences in reporting criteria and thresholds. Some countries require mandatory ADR reporting, while others allow self-reporting by patients. [26] These differences lead to underreporting or overrepresentation of certain ADRs.

The impact of poor data quality and lack of standardization on patient safety, drug regulation, and research includes delayed safety signals, regulatory challenges, ineffective risk management, and increased healthcare costs. [27] To improve data quality and standardization in ADR monitoring, improvements in data collection, reporting standards, and global collaboration are needed.

To enhance data collection and quality, healthcare professionals should be encouraged to report ADRs, using Artificial Intelligence (AI) and big data to detect missing information and improve causality assessments. Implementing digital pharmacovigilance systems can reduce data errors and improve real-time monitoring. [28] Standardizing ADR reporting systems should involve adopting a global ADR reporting platform, harmonizing terminologies, mandating standardized data fields, strengthening regulatory frameworks, and developing AI-driven signal detection systems.

In conclusion, improving data quality and standardization in ADR monitoring is essential for ensuring patient safety, drug regulation, and research. [29]

### 3.3 Ensuring Patient Confidentiality and Data Protection

Adverse Drug Reaction (ADR) monitoring is a crucial aspect of pharmacovigilance, aiding in the detection, analysis, and prevention of medication-related risks. However, ensuring patient confidentiality and data protection becomes increasingly complex due to the increasing use of digital databases, electronic health records, and global data-sharing networks. The risk of patient identification is a primary concern, as certain details like age, gender, geographic location, and rare disease conditions may lead to re-identification. Anonymization and pseudonymization techniques help reduce this risk, but they are not foolproof.

Ethical considerations surrounding patient consent in ADR reporting are another challenge.

Some regulatory frameworks, such as the European Union's General Data Protection Regulation (GDPR), require explicit patient consent for health data processing, while others assume implied consent. This discrepancy creates inconsistencies in global pharmacovigilance practices and may discourage patients from seeking medical care due to concerns about data misuse.

Data sharing with third parties, such as pharmaceutical companies, regulatory agencies, and academic researchers, introduces further risks to patient confidentiality. Improper handling of sensitive information can lead to privacy violations, and improper handling can result in data breaches within these organizations.

The digitalization of ADR monitoring systems increases vulnerability to cybersecurity threats. As electronic health records and online reporting systems become the norm, they become prime targets for cyberattacks. Data breaches in healthcare institutions have been reported worldwide, where hackers gain unauthorized access to confidential medical information. The increasing frequency of ransomware attacks on hospitals and health organizations underscores the urgent need for robust cybersecurity measures to protect ADR monitoring systems from malicious intrusions. [30]

A major limitation in data protection for ADR monitoring is the lack of standardized global regulations. Different countries have varying data protection laws, complicating the implementation of a unified system. Non-compliance with data protection laws can result in penalties for healthcare providers, pharmaceutical companies, and regulatory agencies, further complicating global pharmacovigilance efforts.

## IV. INTERNATIONAL COLLABORATION AND HARMONIZATION

Pharmacovigilance is a global effort to standardize ADR reporting and regulatory practices, ensuring global drug safety. The WHO Programme for International Drug Monitoring (PIDM) coordinates ADR data collection from 170+ countries through VigiBase, aiding early safety signal detection. Organizations like ICH and CIOMS establish global pharmacovigilance guidelines, while regulatory agencies collaborate on post-marketing surveillance. Despite challenges like regulatory differences and data privacy laws, continuous training, capacity building, and technological advancements strengthen global

pharmacovigilance efforts, ensuring safer medicines for all. [30]

#### 4.1 World Health Organization (WHO) and Uppsala Monitoring Centre (UMC)

The World Health Organization (WHO) and the Uppsala Monitoring Centre (UMC) are working together to improve global pharmacovigilance through standardized ADR monitoring systems. The WHO Programme for International Drug Monitoring (PIDM) is established, with UMC serving as its operational hub. The collaboration ensures harmonization of reporting standards using tools like the WHO-UMC causality assessment system and the Medical Dictionary for Regulatory Activities (MedDRA). The WHO and UMC also promote capacity building, training, and regulatory support, especially for low- and middle-income countries. [31]

#### 4.2 International Conference on Harmonisation (ICH) and E2B(R3) Guidelines

The International Council for Harmonisation (ICH) has developed the E2B(R3) guideline, which standardizes the electronic exchange of Individual Case Safety Reports (ICSRs) between regulatory authorities, pharmaceutical companies, and global pharmacovigilance databases. This guideline improves data quality, consistency, and interoperability by defining structured formats for reporting Adverse Drug Reactions (ADRs) using ISO IDMP standards and XML-based messaging. This enhances global pharmacovigilance and faster safety signal detection, thereby strengthening international drug safety monitoring. [32]

#### 4.3 Global Pharmacovigilance and ADR Monitoring Networks

st database for ADR reports. More than 170 countries participate in the WHO-PIDM, contributing data and collaborating on drug safety surveillance. Regional pharmacovigilance networks have been established to enhance ADR reporting and regulatory harmonization. The European Union (EU) uses the EudraVigilance system, while the United States uses the FDA Adverse Event Reporting System (FAERS). [33] Canada operates the Canada Vigilance Program, Japan manages the Japanese Adverse Drug Event Report (JADER) Database, and India promotes ADR monitoring through the Pharmacovigilance Programme of India (PvPI). International collaboration and

harmonized reporting standards are being worked on by organizations like the ICH E2E Guidelines and the International Society of Pharmacovigilance (ISoP). Future directions and challenges include underreporting, data standardization, and regulatory differences. [34]

## V. CONCLUSION

Adverse Drug Reaction (ADR) monitoring is a crucial aspect of pharmacovigilance, enhancing medication safety, patient outcomes, and healthcare systems. It helps in early detection and prevention of harmful drug reactions, reducing hospitalizations, treatment-related complications, and saving lives. ADR monitoring also contributes to drug efficacy by identifying long-term adverse effects not evident during clinical trials. This real-world data supports regulatory agencies in making informed decisions about drug labeling, safety warnings, and market withdrawals. ADR monitoring also reduces healthcare costs by preventing medication-related complications, allowing resources to be allocated more effectively towards preventive care. To maximize its benefits, robust ADR monitoring strategies are essential, including spontaneous reporting systems, active surveillance, artificial intelligence-driven data analysis, and enhanced training programs for healthcare professionals. Encouraging patient participation in ADR reporting fosters a culture of transparency and trust, improving adherence to treatment regimens. Collaboration among regulatory agencies, healthcare professionals, pharmaceutical companies, and patients is essential for strengthening ADR monitoring frameworks at national and international levels. ADR monitoring is not just a regulatory requirement but a fundamental pillar of patient safety and public health.

## REFERENCE

- [1]. Garg, A., Jindal, N., Kaur, S., & Arora, S. (2013). Adverse drug reaction monitoring: Support for pharmacovigilance at a tertiary care hospital in Northern India. *BMC Pharmacology and Toxicology*, 14(1), 5. [articles/10.1186/2050-6511-14-5](https://doi.org/10.1186/2050-6511-14-5)
- [2]. Khalil, H., & Huang, C. (2019). Adverse drug reactions in primary care: A scoping review. *BMC Health Services Research*, 19, 329. <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-019-4651-7>

- [3]. Kaur, S., Kapoor, V., Mahajan, R., & Lal, M. (2022). Adverse drug reaction management in hospital settings: Review on assessment, monitoring, prevention, and reporting. *European Journal of Clinical Pharmacology*, 78(3), 355-373.
- [4]. Sarker, A., Ginn, R., Nikfarjam, A., O'Connor, K., Smith, K., & Gonzalez, G. (2021). Artificial intelligence in pharmacovigilance: A systematic review. *Journal of Biomedical Informatics*, 124, 103932.
- [5]. Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2023). Systematic review and meta-analysis on effectiveness of strategies for addressing underreporting of adverse drug reactions. *Journal of the American Pharmacists Association*, 63(4), 599-611.
- [6]. American Society of Health-System Pharmacists (ASHP). (2022). ASHP Guidelines on Adverse Drug Reaction Monitoring and Reporting. *American Journal of Health-System Pharmacy*, 79(1), e83–e89. Retrieved from
- [7]. Jordan, S., Tunnicliffe, C., & Sykes, A. (2014). Adverse drug reactions: Monitoring and nursing management. *BMJ*, 349, g5019. Retrieved from
- [8]. Sharma, M., Baghel, R., Thakur, S., & Adwal, S. (2021). Surveillance of adverse drug reactions at an adverse drug reaction monitoring centre in Central India: A 7-year surveillance study. *BMJ Open*, 11(10), e052737.
- [9]. Jordan, S., Banner, T., Gabe-Walters, M., Mikhail, J. M., Bradbury, I., & Anthony, G. (2018). Nurse-led medicines' monitoring in care homes study protocol: A process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines. *BMJ Open*, 8(9), e023377.
- [10]. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. *The Lancet*, 356(9237), 1255-1259.
- [11]. Hazell, L., & Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. *Drug Safety*, 29(5), 385-396. DOI: <https://doi.org/10.2165/00002018-200629050-00003>
- [12]. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. *JAMA*, 287(17), 2215-2220.
- [13]. García-Abeijon, P., Costa, C., Taracido, M., Herdeiro, M. T., Torre, C., & Figueiras, A. (2023). Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update. *Drug Safety*, 46(7), 625–636.
- [14]. Gupta, R., Malhotra, A., & Malhotra, P. (2018). A study on determinants of underreporting of adverse drug reactions among resident doctors. *International Journal of Research in Medical Sciences*, 6(2), 432–435.
- [15]. Priyadharsini, R., Raja, T. A. R., & Dhayaguruvasan, M. (2017). A study on awareness of pharmacovigilance and determinants of underreporting of adverse drug reactions by health care professionals and general practitioners. *International Journal of Basic & Clinical Pharmacology*, 6(5), 1227–1232.
- [16]. Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009). Determinants of under-reporting of adverse drug reactions: a systematic review. *Drug Safety*, 32(1), 19–31.
- [17]. Varallo, F. R., Planeta, C. S., & de Carvalho Mastroianni, P. (2014). Causes for the underreporting of adverse drug events by health professionals: a systematic review. *Revista da Associação Médica Brasileira*, 60(3), 217–223.
- [18]. Niazi, S. K., Al-Shaqha, W. M., & Mirza, Z. (2022). Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars. *Journal of Market Access & Health Policy*, 11(1), 2147286.
- [19]. Liu, H., Zheng, M., Li, X., Wang, Q., & Hou, Y. (2019). Overview of Implementation of E2B (R3) Guidelines by ICH Founding Regulatory Members. *Chinese Journal of Pharmacovigilance*, 16(10), 594–596
- [20]. Fermont, I. (2019). Pharmacovigilance strategy: Opportunities for cross-national

- learning. *Israel Journal of Health Policy Research*, 8(1), 1-10.
- [21]. Moore, N., Lecointre, D., Noblet, C., & Mabillet, M. (2001). Adverse drug reactions monitoring: Prospects and impending challenges for pharmacovigilance. *Drug Safety*, 24(7), 519-532.
- [22]. Elumalai, M. (2022). Pharmacovigilance and drug safety: Current practices and future directions. *IASR Journal of Medical and Pharmaceutical Science*, 2(4), 44-50.
- [23]. Salimi, M. (2023). Global collaboration in pharmacovigilance: A new paradigm for safety. *Journal of Pharmacovigilance*, 11(2), 1-5.
- [24]. Mouton, A., Bégau, B., & Pariente, A. (2023). Unveiling the future: Precision pharmacovigilance in the era of personalized medicine. *Journal of Translational Medicine*, 21(1), 1-12.
- [25]. Mir, M. A., Dar, M. A., Qadir, A., Qadrie, Z., & Ashraf, H. (2022). Adverse Drug Reaction Monitoring and Assessment in Clinical Settings. *Journal of Community Pharmacy Practice*, 2(03), 7–17.
- [26]. Chandrabhan, Jain, P., & Jain, S. (2021). Adverse Drug Reaction Monitoring Study in Hospitalized Patients: Support for Pharmacovigilance at a Tertiary Care Hospital. *International Journal of Basic & Clinical Pharmacology*, 10(3), 261–265.
- [27]. Shareef, S. M., Naidu, C. D. M., Raikar, S. R., Rao, Y. V., & Devika, U. (2017). Development, Implementation, and Analysis of Adverse Drug Reaction Monitoring System in a Rural Tertiary Care Teaching Hospital in Narketpally, Telangana. *International Journal of Basic & Clinical Pharmacology*, 4(4), 757–760.
- [28]. Sahu, R. K., Yadav, R., Prasad, P., Roy, A., & Chandrakar, S. (2014). Adverse Drug Reactions Monitoring: Prospects and Impending Challenges for Pharmacovigilance. *SpringerPlus*, 3, 695.
- [29]. Wasiullah, M., Kushwaha, S. K., Yadav, D. J., & Yadav, P. (Year not specified). A Review on Healthcare Professional Approaches in Adverse Drug Reaction Monitoring and Reporting System. *International Journal of Pharmacology and Clinical Research*.
- [30]. Mukadam, F. M., & Gawali, U. P. (2024). Adverse Drug Reactions: A Retrospective Analysis from the ADR Monitoring Centre at a Tertiary Care Hospital. *Journal of Pharmaceutical Care*, 12(1), 3–8.
- [31]. Hassan, A., Batool, A., Sheikh, A. S., Ullah, H., Akhtar, M. M., Rahman, A. U., et al. (2024). Impact of Pharmacovigilance in Monitoring Adverse Drug Reactions: A Retrospective Study. *Journal of Population Therapeutics and Clinical Pharmacology*, 31(1).
- [32]. Chandrabhan, Jain, P., & Jain, S. (2021). Adverse Drug Reaction Monitoring Study in Hospitalized Patients: Support for Pharmacovigilance at a Tertiary Care Hospital. *International Journal of Basic & Clinical Pharmacology*, 10(3), 261–265.
- [33]. Patel, P., & Patel, T. (2025). A Pharmacovigilance Study on Adverse Drug Reaction Profile at a Tertiary Care Teaching Hospital from Western Part of India. *International Journal of Pharmaceutical Investigation*, 15(1).
- [34]. Gupta, S. K., Nayak, R. P., Shivarajani, R., & Vidyarthi, S. K. (2013). Evaluation of Awareness about Pharmacovigilance and Adverse Drug Reaction Monitoring in Resident Doctors of a Tertiary Care Teaching Hospital. *Perspectives in Clinical Research*, 4(4), 184–189.